230 related articles for article (PubMed ID: 35122059)
1. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer.
Tu M; Klein L; Espinet E; Georgomanolis T; Wegwitz F; Li X; Urbach L; Danieli-Mackay A; Küffer S; Bojarczuk K; Mizi A; Günesdogan U; Chapuy B; Gu Z; Neesse A; Kishore U; Ströbel P; Hessmann E; Hahn SA; Trumpp A; Papantonis A; Ellenrieder V; Singh SK
Nat Cancer; 2021 Nov; 2(11):1185-1203. PubMed ID: 35122059
[TBL] [Abstract][Full Text] [Related]
2. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer.
Krebs N; Klein L; Wegwitz F; Espinet E; Maurer HC; Tu M; Penz F; Küffer S; Xu X; Bohnenberger H; Cameron S; Brunner M; Neesse A; Kishore U; Hessmann E; Trumpp A; Ströbel P; Brekken RA; Ellenrieder V; Singh SK
JCI Insight; 2022 Aug; 7(16):. PubMed ID: 35993361
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.
Camolotto SA; Belova VK; Torre-Healy L; Vahrenkamp JM; Berrett KC; Conway H; Shea J; Stubben C; Moffitt R; Gertz J; Snyder EL
Gut; 2021 May; 70(5):900-914. PubMed ID: 32826305
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H
Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of PDAC subtype heterogeneity and therapy response.
Espinet E; Klein L; Puré E; Singh SK
Trends Cancer; 2022 Dec; 8(12):1060-1071. PubMed ID: 36117109
[TBL] [Abstract][Full Text] [Related]
6. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
7. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
8. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8.
Chen SJ; Lian GD; Li JJ; Zhang QB; Zeng LJ; Yang KG; Huang CM; Li YQ; Chen YT; Huang KH
Cancer Med; 2018 Nov; 7(11):5679-5690. PubMed ID: 30311406
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
10. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
11. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
12. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment.
Le Large TY; Mato Prado M; Krell J; Bijlsma MF; Meijer LL; Kazemier G; Frampton AE; Giovannetti E
Expert Rev Mol Diagn; 2016 Jul; 16(7):733-6. PubMed ID: 27118062
[TBL] [Abstract][Full Text] [Related]
14. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma.
Zhang J; Sun H; Liu S; Huang W; Gu J; Zhao Z; Qin H; Luo L; Yang J; Fang Y; Ge J; Ni B; Wang H
Aging (Albany NY); 2020 Nov; 12(22):23217-23232. PubMed ID: 33221741
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.
Jiang Z; Zhou C; Cheng L; Yan B; Chen K; Chen X; Zong L; Lei J; Duan W; Xu Q; Li X; Wang Z; Ma Q; Ma J
J Exp Clin Cancer Res; 2018 Mar; 37(1):69. PubMed ID: 29587800
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
